drugset

drugset / Trial / NCT05466643

A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus

NCT05466643 ↗

Phase 3 Unknown 240 enrolled Daewoong Pharmaceutical Co. LTD.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A multicenter, randomized, placebo-controlled clinical trial, double-blind, parallel-group

Timeline

Start: 2023-03-17
Primary completion: 2024-09-30
Completion: 2024-09-30

Publications

Hong JH, Min KW, Lee CB, Chamnan P, Sirirak T, Sony K, Sattanon S, Kim HJ, Kim SY, Kim Y, Heo JA, Cho JM, Nah JJ, Park MH, Kim JH. Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs. Diabetes Metab J. 2025 Dec 15. doi: 10.4093/dmj.2025.0477. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Enavogliflozin	Small molecule	0.3 mg	Oral

Indications